Antimicrobial Peptides are molecules that form part of host defense mechanism in prokaryotic as well as eukaryotic cells capable of protecting against the harmful infective threats modelled by the bacteria, viruses and even fungi. The mode of action highly depends on the composition of antimicrobial peptides and hence utilized to target cytoplasmic membranes, cell walls, DNA and proteins.
This makes antimicrobial peptides useful molecules to design assays, therapies and combination treatment via immunomodulation. The activation, elicitation and suppression of biological systems is gaining significant value in pharmaceutical as well as clinical applications to treat obscure oncological and rare maladies.
The cost of manufacturing antimicrobial peptides is more than the cost of manufacturing other pharmaceuticals for therapeutic utility depending on the target specificity. The business model for antimicrobial peptides is different than what is present in the pharmaceutical market owing to the novelty of the assays and techniques implemented.
The research process and designing the therapy process for commercialization is different, moreover the industry requires a more vigorous approach in order to create an entry and further access to the developing markets. Manufacturers of the antimicrobial peptides dependent therapy spend the majority their resources on upgrading the associated technology.
The opportunities present in developing antimicrobial peptides are more as compared to threats prevalent. The application of antimicrobial peptides in ailment of Hepatitis C, pneumonia, bacterial infections, HIV AIDS and cancer is expected to surge the acceptance towards the therapies.
The institutional research is heavily invested with rising pool of scientists and skilled technocrats interested in the domain for novel drugs involving antimicrobial peptides for rare diseases. The one of the pluses that include are antimicrobial peptides can be developed for a range of utilities ranging from increasing the shelf-life in food packaging to delivery of bioactive compounds in therapeutic sectors driving the market.
The growing antibiotic resistance, synthetic approaches, innovative formulations and drug delivery routes are the factors expected to drive the growth.
The global market for antimicrobial peptides is estimated to experience a significant growth due to the increase in awareness and access towards drugs and therapies involving antimicrobial peptides. Chronic diseases where antibiotic resistance is not fruitful creates a more lucrative opportunity for manufactures present in the antimicrobial peptides market.
The current structure of the antimicrobial peptides market include drugs targeted towards pneumonia, Hepatitis C, HIV and bacterial infections. Each of the antimicrobial peptides uses different type of mechanism and are used to deliver better clinical results.
Geographically, the Antimicrobial Peptides market is segmented into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa. Each country is equally important to drive the market for antimicrobial peptides, advanced or emerging healthcare settings help in restoring the market and increase the reach to a wider section of patients in need.
The distribution channel is an important part for antimicrobial peptides; the developed markets focus on the applications wherein the antimicrobial resistance is compromised whereas the emerging markets are more focused towards the reach and affordability of antimicrobial peptides.
The North America region is estimated to have a significant share in the antimicrobial peptides market, owing to its quality infrastructure supporting the need of antimicrobial peptides research activities undertaken. It is followed by Europe, East Asia and Oceania.
The South Asia antimicrobial peptides market would translate as a lucrative market opportunity for manufacturers, as well as industry experts, with present change in adoption and growth in general pharmaceutical market.
The key players involved in the market of antimicrobial peptides market include Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, EnBiotix Inc., Johnson & Johnson Services, Merck & Co., Alexion Pharmaceuticals, Inc., Melinta Therapeutics, Inc., and Vertex Pharmaceuticals, Inc. The present market structure of antimicrobial peptides is expected to change with efforts and research present in clinical phase.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.
Tentatively, the global antimicrobial peptides market has been segmented on the basis of ailments, distribution channel, route of administration and geography.
Based on ailments, the antimicrobial peptides market is segmented as:
Based on distribution channel, the global antimicrobial peptides market is segmented as:
Based on rote of administration, the global antimicrobial peptides market is segmented as:
Explore Similar Insights
Antimicrobial Peptides Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
